#USA #New York #Faruqi & Faruqi #LLP #Iovance Biotherapeutics

Overview of the Investigation

Faruqi & Faruqi, LLP, a nationally recognized securities law firm, is currently looking into possible claims on behalf of investors who have experienced losses from their investments in Iovance Biotherapeutics, Inc. This investigation comes in light of alarming revelations regarding the company’s ability to meet its growth projections and treatment demand. The deadline for interested investors to step forward is July 14, 2025, marking the cutoff for filing a lead plaintiff role within a federal securities class action lawsuit against the company.

Background on Iovance Biotherapeutics

Iovance Biotherapeutics (NASDAQ: IOVA) specializes in developing innovative cell therapy treatments for cancer. Despite its promising therapeutic approaches, the firm’s recent financial disclosures have raised significant concerns among investors. On July 25, 2024, the corporation announced its second-quarter results, which unexpectedly revealed a drastic revision of its revenue forecasts for fiscal year 2024. Iovance attributed the downgrades to a combination of factors, including operational challenges and lower-than-expected sales performance.

Key Allegations Against Iovance

The investigations highlight critical allegations that Iovance and its executives might have breached federal securities laws. Reports indicate that the company may have disseminated misleading information about its market position and growth potential. Notably, there are claims that Iovance was inadequately prepared to capitalize on the existing demand for its therapies, which is primarily facilitated through a network of approved treatment centers.

The fallout from Iovance’s disappointing projections was immediate and severe. Following the company’s announcement, its stock plummeted nearly 45% in a single day, from a closing price of $3.17 per share on May 8, 2025, to $1.75 per share the following day. Such a drastic decrease illustrates the market’s reaction to investors’ lack of confidence in Iovance’s ability to generate revenue as initially promised.

Legal Action and Options for Investors

Faruqi & Faruqi advises any investor who lost over $100,000 in Iovance stocks between August 8, 2024, and May 8, 2025, to reach out for a discussion about their legal options. This includes potential participation in the class action lawsuit designed to seek compensation for incurred losses. The law firm explains that each investor's ability to share in any recovery is not influenced by whether they decide to take on the role of lead plaintiff.

Investors also have the opportunity to submit information pertaining to Iovance’s operations, as the firm is open to tips from whistleblowers, former employees, and shareholders who may have insights into the company’s practices. This may further aid in building the case against Iovance Biotherapeutics.

Next Steps for Investors

Potential class members interested in pursuing legal recourse are encouraged to act promptly due to the approaching deadline. Faruqi & Faruqi, LLP emphasizes that any information provided will be treated confidentially. To learn more about the ongoing investigation or to consult directly with an attorney, investors are urged to visit Faruqi & Faruqi’s dedicated webpage for Iovance or contact Josh Wilson, a partner at the firm, at 877-247-4292 or 212-983-9330 (Extension 1310).

Conclusion

In a rapidly evolving biotech market, the implications of these allegations against Iovance Biotherapeutics stand to reshape investor trust and regulatory considerations in public offerings. While Faruqi & Faruqi’s investigation is in its early stages, the outcome could have significant ramifications for both the company’s future and the investors it affects. Remember, being informed and proactive is essential in navigating potential legal remedies in times of corporate turbulence. Investors must remain vigilant as the deadline approaches to safeguard their interests and pursue justice.

• ---